Prana must be careful not to give away a fortune in cost saving by assuming there will be required a phase III trial. If we assume that, at a very high cost, and FDA accelerates PBT2 straight to market, it should not be Big Pharma winner take all. Such is the complexity of negotiations - you must consider all possibilities and get them in writing as to what will occur, or what is priced in, or how to do a deal where Prana gets more if there is no need for a phase III trial. That is my biggest concern in a partnership is to cut a deal assuming this enormous cost model presente by Big Pharma that may not transpire.
Prana must be careful not to give away a fortune in cost saving...
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.001(25.0%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $625 | 125K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 63 | 72318906 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 29668676 | 22 |
View Market Depth
| Last trade - 10.00am 09/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |